Silverarc Capital Management
Silverarc Capital Management reported 63 stocks worth $821M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are KOD (8.7%), CELC (7.8%) and COGT (6.1%). Compared with Q2 2026, the fund opened new positions in CLDX, RNAQU and YARW, added to KOD, CELC and COGT, trimmed URGN, ASND and DNTH and sold out of VCYT, GH and TRVI.
Latest filing: what Silverarc Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KOD Kodiak Sciences Inc | $71.1M | 8.7% | 750K | +204K (+37%) | 8 of 8 | |
| 2 | ![]() CELC Celcuity Inc | $63.9M | 7.8% | 803K | +302K (+60%) | 5 of 8 | |
| 3 | ![]() COGT Cogent Biosciences Inc | $50.4M | 6.1% | 1.6M | +294K (+23%) | 6 of 8 | |
| 4 | ![]() URGN Urogen Pharma Ltd | $46.7M | 5.7% | 1.1M | −153K (−12%) | 8 of 8 | |
| 5 | ![]() IMNM Immunome Inc | $45M | 5.5% | 2.1M | +76K (+4%) | 4 of 8 | |
| 6 | ![]() GLUE Monte Rosa Therapeutics Inc | $37.1M | 4.5% | 3.1M | +2M (+181%) | 5 of 8 | |
| 7 | ![]() SGMT Sagimet Biosciences Inc | $37M | 4.5% | 3.7M | +818K (+28%) | 3 of 8 | |
| 8 | ![]() ASND Ascendis Pharma A/s | $34.7M | 4.2% | 152K | −54K (−26%) | 2 of 8 | |
| 9 | ![]() RYTM Rhythm Pharmaceuticals Inc | $33.2M | 4.0% | 348K | +37K (+12%) | 8 of 8 | |
| 10 | ![]() BIIB Biogen Inc | $25.5M | 3.1% | 113K | +65K (+134%) | 5 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() VCYT Veracyte Inc | $18.7M | 318K |
![]() GH Guardant Health Inc | $15M | 100K |
![]() TRVI Trevi Therapeutics Inc | $12.6M | 678K |
![]() MANE Veradermics Inc | $11.7M | 95K |
![]() XENE Xenon Pharmaceuticals Inc | $11.3M | 187K |
🔒 Free account: see all 17.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() CLDX Celldex Therapeutics Inc New | Call | $12M | 371K | +370,700 |
![]() ORIC Oric Pharmaceuticals Inc | Call | $9.5M | 702K | +19,800 |
![]() GLUE Monte Rosa Therapeutics Inc | Call | $6.3M | 525K | +225,000 |
![]() ABSI Absci Corporation | Put | $2.7M | 255K | +97,100 |
![]() FULC Fulcrum Therapeutics Inc | Call | $1.5M | 392K | 0 |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 12, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Silverarc Capital Management 13F FAQ
What does Silverarc Capital Management own?
Silverarc Capital Management reported 63 stocks worth $821M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are KOD (8.7%), CELC (7.8%) and COGT (6.1%). The table above lists every position in the filing (the top 10 without an account).
What did Silverarc Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 15 new positions, 26 added to, 20 trimmed and 17 sold out. New positions include CLDX, RNAQU and YARW. It sold all of VCYT, GH and TRVI.
When will Silverarc Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Silverarc Capital Management's portfolio worth?
The Q3 2026 filing reports $821M in US stocks ($854M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.


























